All eyes are on the scheduled release of BioNTech's fourth-quarter and full-year 2025 financial results, set for March 10, 2026. The accompanying conference call will occur during a period of intense ...
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...
BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...
Investors in BioNTech SE are preparing for a key financial update, with the company confirming it will release its fourth-quarter and full-year 2025 results on ...
The release of the fourth quarter and full-year 2025 results will serve as a comprehensive health check, moving beyond quarterly performance to evaluate the company's broader strategic pivot. The core ...
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking at the J.P. Morgan Healthcare Conference in San Francisco, ...
MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data from the non-pivotal dose-confirmation ...
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy ...
BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results